Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England

被引：8
作者：
Harman, Katie [1 ]
Nash, Sophie Grace [1 ]
Webster, Harriet H. [1 ]
Groves, Natalie [2 ]
Hardstaff, Jo [3 ]
Bridgen, Jessica [3 ]
Blomquist, Paula B. [3 ]
Hope, Russell [1 ]
Ashano, Efejiro [4 ]
Myers, Richard [2 ]
Rokadiya, Sakib [5 ]
Hopkins, Susan [6 ]
Brown, Colin S. [7 ,8 ]
Chand, Meera [2 ]
Dabrera, Gavin [1 ]
Thelwall, Simon [1 ]
机构：
[1] UKHSA COVID-19 Natl Epidemiol Cell, 61 Colindale Ave, London, England
[2] UKHSA Genom & Publ Hlth Anal, London, England
[3] UKHSA Outbreak Surveillance Team, London, England
[4] UKHSA HCAI, Fungal AMR AMU & Sepsis Div, London, England
[5] UKHSA COVID-19 Therapeut, London, England
[6] UKHSA, London, England
[7] UKHSA HCAI, Fungal AMR AMU & Sepsis Div, London, England
[8] NIHR Hlth Protect Res Unit Healthcare Associated I, London, England
来源：
INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2023年 / 17卷 / 05期
基金：
英国医学研究理事会;
关键词：
COVID-19; therapeutics; neutralising monoclonal antibodies; SARS-CoV-2; severity;
D O I：
10.1111/irv.13150
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.
引用
收藏
页数：6
相关论文
共 15 条
  • [1] Cabinet Office, COVID-19 Response: Living with COVID-19 2022
  • [2] Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England
    Clare, T.
    Twohig, K. A.
    O'connell, A-M
    Dabrera, G.
    [J]. PUBLIC HEALTH, 2021, 194 : 163 - 166
  • [3] Department of Health and Social Care, INT CLIN COMM POL AN
  • [4] Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
    Gupta, Anil
    Gonzalez-Rojas, Yaneicy
    Juarez, Erick
    Casal, Manuel Crespo
    Moya, Jaynier
    Falci, Diego R.
    Sarkis, Elias
    Solis, Joel
    Zheng, Hanzhe
    Scott, Nicola
    Cathcart, Andrea L.
    Hebner, Christy M.
    Sager, Jennifer
    Mogalian, Erik
    Tipple, Craig
    Peppercorn, Amanda
    Alexander, Elizabeth
    Pang, Phillip S.
    Free, Almena
    Brinson, Cynthia
    Aldinger, Melissa
    Shapiro, Adrienne E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) : 1941 - 1950
  • [5] Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
    Martin-Blondel, Guillaume
    Marcelin, Anne-Genevieve
    Soulie, Cathia
    Kaisaridi, Sofia
    Lusivika-Nzinga, Clovis
    Dorival, Celine
    Nailler, Laura
    Boston, Anais
    Melenotte, Clea
    Gaube, Geraldine
    Choquet, Christophe
    Liblau, Roland
    Carrat, Fabrice
    Yordanov, Youri
    [J]. JOURNAL OF INFECTION, 2022, 84 (06) : E101 - E104
  • [6] Medicines and Healthcare products Regulatory Agency, REG APPR XEV SOTR
  • [7] National Institute for Health and Care Excellence BNF, SOTR
  • [8] NHS England, COVID 19 THER ANT NE
  • [9] Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
    Nyberg, Tommy
    Ferguson, Neil M.
    Nash, Sophie G.
    Webster, Harriet H.
    Flaxman, Seth
    Andrews, Nick
    Hinsley, Wes
    Bernal, Jamie Lopez
    Kall, Meaghan
    Bhatt, Samir
    Blomquist, Paula
    Zaidi, Asad
    Volz, Erik
    Aziz, Nurin Abdul
    Harman, Katie
    Funk, Sebastian
    Abbott, Sam
    Hope, Russell
    Charlett, Andre
    Chand, Meera
    Ghani, Azra C.
    Seaman, Shaun R.
    Dabrera, Gavin
    De Angelis, Daniela
    Presanis, Anne M.
    Thelwall, Simon
    [J]. LANCET, 2022, 399 (10332) : 1303 - 1312
  • [10] Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
    Takashita, Emi
    Kinoshita, Noriko
    Yamayoshi, Seiya
    Sakai-Tagawa, Yuko
    Fujisaki, Seiichiro
    Ito, Mutsumi
    Iwatsuki-Horimoto, Kiyoko
    Halfmann, Peter
    Watanabe, Shinji
    Maeda, Kenji
    Imai, Masaki
    Mitsuya, Hiroaki
    Ohmagari, Norio
    Takeda, Makoto
    Hasegawa, Hideki
    Kawaoka, Yoshihiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) : 1475 - 1477
12